Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease

While the past decade has seen meaningful improvements in clinical outcomes for multiple myeloma patients, a subset of patients does not benefit from current therapeutics for unclear reasons. Many gene expression-based models of risk have been developed, but each model uses a different combination o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mason, Mike J., Schinke, Carolina, Eng, Christine L. P., Towfic, Fadi, Gruber, Fred, Dervan, Andrew, White, Brian S., Pratapa, Aditya, Guan, Yuanfang, Chen, Hongjie, Cui, Yi, Li, Bailiang, Yu, Thomas, Chaibub Neto, Elias, Mavrommatis, Konstantinos, Ortiz, Maria, Lyzogubov, Valeriy, Bisht, Kamlesh, Dai, Hongyue Y., Schmitz, Frank, Flynt, Erin, Dan Rozelle, Danziger, Samuel A., Ratushny, Alexander, Dalton, William S., Goldschmidt, Hartmut, Avet-Loiseau, Herve, Samur, Mehmet, Hayete, Boris, Sonneveld, Pieter, Shain, Kenneth H., Munshi, Nikhil, Auclair, Daniel, Hose, Dirk, Morgan, Gareth, Trotter, Matthew, Bassett, Douglas, Goke, Jonathan, Walker, Brian A., Thakurta, Anjan, Guinney, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326699/
https://www.ncbi.nlm.nih.gov/pubmed/32060406
http://dx.doi.org/10.1038/s41375-020-0742-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326699/
https://www.ncbi.nlm.nih.gov/pubmed/32060406
http://dx.doi.org/10.1038/s41375-020-0742-z

Ejemplares similares